Virus-related liver cirrhosis: Molecular basis and therapeutic options

Ji Lin, Jian-Feng Wu, Qi Zhang, Hong-Wei Zhang, Guang-Wen Cao

Abstract

Chronic infections with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) are the major causes of cirrhosis globally. It takes 10-20 years to progress from viral hepatitis to cirrhosis. Intermediately active hepatic inflammation caused by the infections contributes to the inflammation-necrosis-regeneration process, ultimately cirrhosis. CD8+ T cells and NK cells cause liver damage via targeting the infected hepatocytes directly and releasing pro-inflammatory cytokine/chemokines. Hepatic stellate cells play an active role in fibrogenesis via secreting fibrosis-related factors. Under the inflammatory microenvironment, the viruses experience mutation-selection-adaptation to evade immune clearance. However, immune selection of some HBV mutations in the evolution towards cirrhosis seems different from that towards hepatocellular carcinoma. As viral replication is an important driving force of cirrhosis pathogenesis, antiviral treatment with nucleos(t)ide analogs is generally effective in halting the progression of cirrhosis, improving liver function and reducing the morbidity of decompensated cirrhosis caused by chronic HBV infection. Interferon-α plus ribavirin and/or the direct acting antivirals such as Vaniprevir are effective for compensated cirrhosis caused by chronic HCV infection. The standard of care for the treatment of HCV-related cirrhosis with interferon-α plus ribavirin should consider the genotypes of IL-28B. Understanding the mechanism of fibrogenesis and hepatocyte regeneration will facilitate the development of novel therapies for decompensated cirrhosis.

Key words: Liver cirrhosis; Hepatitis B virus; Hepatitis C virus; Evolution; Immune cells; Signaling pathway; Hepatic stellate cells; Antiviral therapy

Core tip: Hepatic inflammation caused by viral infections contributes to the inflammation-necrosis-regeneration process, ultimately cirrhosis. Immune selection of some hepatitis B virus mutations in the evolution towards cirrhosis seems different from that towards hepatocellular carcinoma. Hepatic stellate cells and macrophages are important for the fibrogenesis. Antiviral treatment is generally effective in reducing the morbidity of decompensated cirrhosis. The standard of care for the treatment of hepatitis C virus-related cirrhosis with pegylated interferon-α and ribavirin should consider the genotypes of IL-28B. Stem cell-based therapy can be an option for the treatment of decompensated cirrhosis patients who fail to respond to antiviral treatment.

INTRODUCTION

Liver cirrhosis represents a worldwide public health...
problem and its mortality rate increases stably these years. Alcoholic hepatitis, non-alcoholic steatohepatitis, and chronic infection with hepatitis C virus (HCV) are the major causes of cirrhosis in Western countries, while chronic infection with hepatitis B virus (HBV) contributes greatly to cirrhosis in HBV-endemic areas. Chronic HBV and HCV infections account for 57% of cirrhosis cases globally[11]. There are about 300 million subjects chronically infected with HBV and 130-170 million subjects chronically infected with HCV worldwide. About one million people die from diseases related to chronic HBV and/or HCV infections each year, mostly end-stage liver diseases, namely, decompensated cirrhosis, liver failure, and hepatocellular carcinoma (HCC). In East Asia where HBV genotypes B and C are endemic, HBV genotype B is more apt to cause acute infection in young people and to be cleared than genotype C; whereas HBV genotype C leads to higher persistence following an acute course and is more apt to cause cirrhosis and HCC compared to genotype B[2-5]. HBV genotype C is associated with a lower rate of spontaneous hepatitis B e antigen (HBBeAg) seroconversion than HBV genotype B. Cirrhosis is specifically found in HBBeAg-negative subjects and more frequently found in subjects with genotype C than in those with genotype B. In HBBeAg-negative subjects, high viral load is frequently associated with abnormal alanine aminotransferase (ALT) level, while ALT abnormality is more frequent in those with cirrhosis than those without[6]. In addition, older age (longer duration of infection), high levels of HBV DNA, habitual alcohol consumption, and concurrent infection with HCV, hepatitis D virus or human immunodeficiency virus are significantly associated with an increased rate of cirrhosis[7]. Most (70%-80%) HCV infections may persist and about 30% of individuals with persistent HCV infection will develop end-stage liver diseases, including cirrhosis and HCC. According to the most recent classification criteria, HCV variants are classified into 6 genotypes, of which HCV-1b is the most recent classification criteria, HCV variants are classified into 6 genotypes, of which HCV-1b is the most common one worldwide[8]. HCV genotype 1b has been associated with an increased risk of HCC in both European and Asian populations[9,10], but it remains uncertain if this genotype of HCV is specifically related to fibrosis and cirrhosis. An interesting cross-sectional study carried out in mainland China indicated that co-infection with HBV, low HCV viral load, low serum ALT, high serum aspartate aminotransferase, diabetes, and high picked food consumption were significantly associated with the risk of cirrhosis in HCV-infected patients[11]. Since both HBV and HCV are preferentially hepatotropic, not directly cytopathic, virus-caused liver damage is attributed to immune-mediated mechanisms. Under inflammatory microenvironment caused by the infections, the continuous infiltration of immune cells and the secreted inflammatory cytokines result in liver damage. The hepatic lobule reconstruction following the damage promotes hepatic fibrosis and eventually leads to cirrhosis. Cirrhosis represents a consequence of wound-healing response to chronic stimulation. It is generally believed that cirrhosis is the outcome of interaction between liver damage and tissue repair. Hepatic satellite cells (HSCs) play a critical role in the progression of cirrhosis. However, the mechanisms by which HSCs modulate fibrogenesis and cirrhosis are less clarified. Active viral replication and intermediate inflammatory reactions facilitate hepatic fibrogenesis but the evolution of fibrogenesis might depart from HCC evolution[12]. In this paper, we focus on virus-related cirrhosis and summarize recent progress on its molecular basis. Moreover, we also discuss possible therapeutic options for hepatic fibrosis, early cirrhosis, and even decompensated cirrhosis.

MOLECULAR BASIS OF VIRUS-RELATED CIRRHOSIS

Immune response and liver damage
Roles of immune cells and cytokines: The immune system is a complicated dynamic network constituted by various immune cells and cytokines. T and B lymphocytes, macrophages (macrophages residing in the liver are also called Kuffer cells), NK cells, neutrophils, HSCs, NK2 cells, dendritic cells (DCs), and mast cells are all important in the maintenance of chronic inflammation. CD8+ cytotoxic T lymphocytes (CTLs) and CD4+ T helper lymphocyte subpopulations [Th1, Th2, Th17, and regulatory T (Treg) cells] also play key roles in maintaining chronic inflammation. The immune effectors not only play critical roles in the HBV and HCV clearance, but also participate in liver damage. Toll-like receptors (TLR)-3 and -7 can recognize the viruses and induce the production of type I interferon (IFN) (IFN-α/β), proinflammatory cytokines and chemokines to inhibit the viruses[13-15], whereas TLR-4 activation by lipopolysaccharides (LPS) in HSCs enhances TGF-β signaling and hepatic fibrosis[16]. TGF-β, a pleiotropic cytokine produced by immune and non-immune cells, has receptors on several cell types. It induces fibrosis via increasing Th17 and HSCs and reducing NK cell activation[17]. A study using TLR-9-deficient mouse model has demonstrated that TLR-9 is also involved in liver fibrosis[16]. As important antiviral cytokines activated in the initial immune response, IFN-α/β can inhibit viral replication and lead to death of the infected hepatocytes by inducing the expression of multiple IFN-stimulated genes (ISGs), including protein kinase R (PKR), Mx proteins, ISG-15, RnaseL/2',5'-oligoadenylate synthetase (2',5'-OAS) and RNA helicases[18,19]. Additionally, it may activate the neighboring immune cells, including macrophages, NK cells, NKT cells and DCs[20-22]. Both NK cells and CD8+ CTLs exert immunoregulatory functions via direct, non-MHC-restricted cytotoxic mechanisms and cytokine production[24,25]. IFN-γ and tumor necrosis factor-α (TNFα) produced by NK cells and CD8+ CTLs can not only inhibit the viruses, but also cause liver damage through TNF-related apoptosis-inducing ligand

Lin J et al. Mechanism and treatment of liver cirrhosis

WJG | www.wjgnet.com

June 7, 2014 | Volume 20 | Issue 21 |
Dysfunction of T cells: In the phase of chronic HBV and HCV infections, specific T cells present a condition of dysfunction due to the persistent exposure to high levels of viral antigens that exceed the capacity of host immunity. It may be induced by the following mechanisms. First, genetic predisposition of immune-related genes contributes to persistence of HBV and/or HCV infections. Genetic polymorphism of class I human leukocyte antigen (HLA) has been associated with HBV [30] and HCV persistence/clearance [31], possibly because this genetic predisposition affects T cell function upon HBV infection. Genetic polymorphisms of other immune-related genes, notably, interleukin-28B (IL28B), have closely been associated with HCV clearance, progression, and treatment response [32,33]. Second, antigen presentation by DCs and macrophages may be impaired, resulting in ineffective priming of T cells or deficient maintenance of antigen-experienced T cells [34]. Additionally, dysfunctional specific T cells can express the inhibitory receptor programmed death-1 (PD-1), which inhibits immune activity and induces the apoptosis of T cells [35-37]. Moreover, HCV core protein can inhibit T cell proliferation by binding to the complement receptor gC-1qR [38,39]. During the prolonged infection, the expression of chemokine (C-C) motif ligand (CCL) 17 and 22, attractors for Tregs [40,41], can inhibit the proliferation and function of T cells and other immune cells [42]. The dysfunctional T cells can hardly eliminate HBV or HCV. On the contrary, the consistent but insufficient immune responses break up several balances between the immune cells or cytokines, such as Th1/Th2 cells or Th17/Treg cells, neutrophils/lymphocytes, neutrophils/CD8+ T cells, and Th1/Th2 cytokines [43,44], which induces a high immune pressure and results in the evolution of the viruses during chronic infection.

Role of inflammatory signaling pathways

There are multiple inflammatory signaling pathways and molecules involved in the sustained inflammation caused by chronic infection, including nuclear factor-kB (NF-kB), Wnt/β-catenin, TGF-β/Smad, RAF/MEK/ERK, JAK/STAT, PI3K-AKT/PKB, Ras-MAPK, and Vitamin A [45-48], NF-kB as a dimeric transcription factor can be activated by proinflammatory stimuli, such as TNFα or interleukin-1β (IL-1β) [49]. The activated NF-kB signaling pathway thereafter induced the expression of a series of growth factors and cytokines to regulate the inflammatory response. IL-6 can be released by macrophages and regulate the proliferation and differentiation of liver fibroblasts [49]. The PI3K-AKT/PKB and Ras-MAPK pathways are also important because they are involved in the activation of HSCs. Platelet-derived growth factor (PDGF) can lead to the Ras-MAPK activation by binding its receptor, and the activation of protein kinase C (PKC) family through PI3K-AKT/PKB eventually induces cell proliferation and HSC activation [50]. These signaling pathways and molecules may play an active role in the pathogenesis of HBV- and HCV-related cirrhosis, thus serving as therapeutic targets and prognostic markers.

HBV and HCV escape strategies in chronic infection

Spontaneous clearance of the viruses can be achieved in some infected subjects by an efficient immune response. However, following the early immune response, 70%-80% of HCV infected patients will develop chronic infection [51] and 8.5% of adults with acute hepatitis B will develop chronic infection [52]. Chronic infection of HBV occurs frequently in those who acquired the infection perinatally (90%) or during childhood (20%-30%), when the immune system is thought to be immature [53]. It implies that HBV and HCV can produce a series of strategies to evade the clearance. Under immune pressure, HBV and HCV can evade the immune clearance through persistent viral replication and mutations, making themselves preferably adapt to the inflammatory microenvironment. However, HBV and HCV have different mutation patterns conforming to their distinct viral structures. HCV replicates at a rate of $10^{12-13}$ virions per day. The RNA-dependent RNA polymerase lacks a proofreading function, favoring the Darwinian selection of viral variants by humoral and cellular immune responses [54]. During the phase of acute infection, there is a high rate of nonsynonymous and synonymous substitutions due to the high levels of selective pressure exerted by antibodies and activated T cells, but the rate decreases at continuous infection stage [55]. The HCV E2 glycoprotein is thought to be a major target for HCV-specific antibody. The nucleotide substitutions at the hypervariable HCV E2 region 1 during anti-HCV seroconversion in acutely HCV-infected individuals are intensively correlated with the viral evasion. HBV exists in the form of covalently closed circular DNA (cccDNA) in the nuclei of hepatocytes and exhibits higher frequencies of mutations than other DNA viruses due to the spontaneous error rate of reverse transcriptase. The rate of HBV mutation in HBeAg-positive patients is $1.5 \times 10^{-5} \times 10^{-5}$ nucleotide substitutions/site per year [56] and is even higher in HBeAg-negative patients. Under...
Association of HBV mutations with cirrhosis

HBV DNA consists of four overlapping open reading frames that encoding the envelope (pre-S/S), core (precore/core), polymerase (P), and X proteins, respectively. HBV preS region consists of preS1 and preS2 domains and they are essential for the immune responses because they contain several epitopes for T and/or B cells. In our previous studies, we defined wild-type nucleotides and mutations of HBV genotypes B and C, respectively. A nucleotide with the highest frequency in the sequences of HBV from asymptomatic HBsAg carriers (ASCs) seropositive for HBeAg was termed a wild-type nucleotide because HBeAg-positive HBV has been traditionally treated as a wild-type strain. Under this definition, we found some of the cirrhosis-related HBV mutations (compared to ASCs and CHB patients) and HCC-related HBV mutations (compared to HBV-infected subjects without HCC) in the preS and enhancer II (Enh II)/basal core promoter (BCP)/precore regions. In the preS region, 81.0% of preS1 wild-type nucleotide hotspots of HBV genotype C are significantly associated with an increased risk of cirrhosis, as compared with CHB; 90.5% of preS1 mutations of HBV genotype C are significantly associated with an increased risk of HCC, compared to cirrhosis. Furthermore, wild-type nucleotides A2964C and T3116C are independently associated with an increased risk of cirrhosis, whereas their mutation counterparts C2964A and C3116T are independently associated with an increased risk of HCC. In the Enh II/BCP/precore region of HBV genotype C, C1673T, A1726C, A1727T, C1730G, C1766T, T1768A, C1773T, and C1799G are significantly associated with an increased risk of cirrhosis, compared to CHB; whereas these mutations are inversely associated with HCC risk, compared to cirrhosis. T1768A, A1762T/G1764A, and A1846T are independently associated with an increased risk of cirrhosis. The frequencies of G1652A, T1673C, and G1730C increase successively from the ASC state to CHB to cirrhosis, but significantly decrease in HCC. A study conducted in Taiwan has demonstrated that multiple HBV mutations including preS deletion, T1762/A1764, T1766 and/or A1768 are more often found than a single mutation pattern in the process of progression to cirrhosis. The evidence indicates that immune selection of some viral mutations in HBV evolution towards cirrhosis seems different from that in the evolution towards HCC. Even though, several important HCC-related HBV mutations, namely, preS deletion, C1653T, T1753V, and A1762T/G1764A successively increase in their frequencies during HBV evolution from ASC state, CHB, and cirrhosis to HCC. This reflects the robustness of HBV preS deletion, C1653T, T1753V, and A1762T/G1764A in predicting the entire evolutionary process from ASC state to HCC. Although cirrhosis is an important risk factor of HCC, most of the virus-related cirrhosis patients do not develop HCC. The difference in immune selection of viral mutants between evolutionary processes towards cirrhosis and HCC should be further elucidated.

Our previous study has demonstrated that genetic predisposition to HLA-DP function play an important role in immune selection of cirrhosis-related HBV mutations and a significant effect of HBV mutations on cirrhosis is selectively evident in those with HLA-DP genotypes that promote HBV persistence. HLA class II loci are mainly associated with spontaneous clearance of HBV and HCV. Interestingly, genetic polymorphisms within HLA II loci have been frequently associated with chronic HBV or HCV hepatitis, hepatic fibrosis, and the development of HCC. Thus, HLA-DP affects HBV persistence, regulates immune selection of viral mutations, and influences cirrhosis risk contributed by HBV mutations.

Cirrhosis-related HBV mutations biologically affect the progression from chronic hepatitis to cirrhosis. Approximately 30.9% of S gene mutations occur in the major hydrophilic region of HBs antigen, which can change the epitopes of the three-dimensional structure, and lead to immune escape of HBV. C1766T/T1768A, an independent risk factor of cirrhosis in HBeAg-negative patients, can increase the pre-genome mRNA encapsidation and then promote viral assembly. In addition, the X gene mutations such as G1386M, C1485T, and C1653T, can regulate the NF-kB signaling pathway which plays a crucial role in the progression to cirrhosis or HCC.
Tissue repair and liver fibrosis

Tissue repair following liver damage as a consequence of the inflammation through the accumulation of extracellular matrix (ECM) proteins mainly secreted by HSCs will eventually result in the occurrence of fibrosis. PDGF is the most potent mitogen for HSCs via the Ras-MAPK and PI3K-AKT/PKB signaling pathways. Moreover, TGF-α and epidermal growth factor (EGF) can also stimulate the proliferation of HSCs. The "inactive" HSCs should undergo a process of unidirectional activation, contributing to differentiate into myofibroblast-like phenotypes during fibrosis. TGF-β1, the most important profibrogenic cytokine known for activated HSCs, is mediated by intracellular signaling via Smad proteins. Smad2 and Smad3 proteins are associated with the activated receptor of TGF-β1, whereas Smad7 is an effective inhibitor for TGF-β1 signaling. In addition, TGF-β1 also can increase α1 collagen mRNA stability via p38 MAPK. HSCs also can trigger an activated process via phagocytizing the apoptotic bodies induced by virus infection. The c-Jun N-terminal kinase-1 (Jnk1) as a profibrotic kinase in HSCs, but not in hepatocytes, significantly contributes to liver fibrosis development. JNK is involved in HSC activation and fibrogenesis and represents a potential target for antifibrotic treatments. These fibrosis-promoting proteins will increase the secretion of fibrillar collagens, resulting in the deposition of excess fibrotic matrix. The activated HSCs also can inhibit the expression of matrix metalloproteinases (MMPs)-2, -9 and -14 which play a role because of proteolytic activity towards ECM, via promoting the expression of tissue inhibitors of metalloproteinases (TIMPs), thus inhibit the matrix degradation. The characteristics of HSC-mediated fibrogenesis result in disruption of the original architecture and liver dysfunction (Figure 1).

Macrophages also are critical for both liver damage and fibrosis. The proinflammatory cytokines interleukin-1β (IL-1β) and IL-18, which induced by macrophages in HCV-infected patients, can promote the inflammation via the NF-κB signaling pathway, resulting in liver damage. Activated macrophages release growth factors, cytokines and chemokines which induce the recruitment of monocytes, thus affecting the function of HSCs and fibroblasts. In particular, TGF-β1 and insulin-like growth factor can activate the fibroblasts and promote a switch in fibroblast gene expression to initiate matrix remodeling. Macrophages display a key role in the different stages of fibrosis and these characteristics may be induced by either different cytokines in the microenvironment or the populations of macrophages. On the other hand, macrophages can exert antifibrotic activity and promote the resolution of fibrosis by producing interstitial collagenases like MMP13. In addition, the phagocytosis of apoptotic hepatocytes has been shown to inhibit the development of fibrosis. Understanding the mechanism of fibrogenesis may pave the way for the treatment of cirrhosis.

THERAPEUTIC OPTIONS FOR VIRUS-RELATED LIVER CIRRHOSIS

Without appropriate therapy for cirrhosis caused by HBV and/or HCV infections, liver injury may persist, thus facilitating the development of decompensated cirrhosis and HCC, especially in those with active viral replication. As viral replication is an important driving force of cirrhosis development, antiviral treatment should be...
carried out before progression into decompensated cirrhosis [77,78]. In addition, as some signaling systems, such as JNK, have been recently associated with the formation of cirrhosis [86-88], targeting these signaling systems might be an important option for the treatment of liver fibrosis and cirrhosis.

**Antiviral treatment of HBV-related compensated cirrhosis**

Around 30%-70% of the patients with compensated liver cirrhosis still have active viral replication, and this active viral replication promotes the progression of liver injury. Successful antiviral treatment prior to the development of cirrhosis is able to greatly reduce the morbidity and mortality of HBV-related end-stage liver diseases. Currently approved nucleos(t)ide analogs (NAs) for the treatment of HBV-related diseases include lamivudine (LAM), adefovir dipivoxil (ADV), entecavir (ETV), telbivudine (TBV), and tenofovir disoproxil fumarate (TDF) [77,78]. Antiviral therapy using newer NAs with lower resistance rates can suppress replication and re-activation of HBV, improve liver function, and restore many patients to a state of well compensated cirrhosis [79,80]. Long-term antiviral therapy can prevent the development of liver decompensation in patients with compensated cirrhosis [77]. The antiviral treatment to halt the progression of compensated cirrhosis should be carried out as early as the diagnosis has been confirmed.

**Antiviral treatment of HBV-related decompensated cirrhosis**

About 2%-5% of patients with HBV-related compensated cirrhosis developed decompensation every year [81]. The prognosis of patients with decompensated cirrhosis is usually poor, with a 5-year survival rate of 14%-35% [82]. All oral antivirals can prevent viral replication efficaciously and improve biochemical and clinical parameters in patients with viral-related decompensated cirrhosis. The selection of antivirals with high efficiency and a low rate of resistance is necessary to attain fast and enduring viral suppression. The use of LAM or TBV is restricted by drug resistance. ADV is restricted by its slower initiation of effect and potential risk of re-infection, which is fatal in decompensated patients. Furthermore, with the more use of TBV, serum creatinine phosphokinase levels frequently increase. Therefore, TBV should be used as a second-line drug for patients with decompensated cirrhosis because of the safety is not guaranteed. A meta-analysis of clinical trials on NA-naive patients with HBsAg-positive CHB has demonstrated that TDF is associated with the highest probability of achieving undetectable HBV DNA at 1 year of all NAs considered [83]. A randomized open-label study has shown that ETV has a virological efficacy precedence that of ADV in HBV-related hepatic decompensation [84]. TDF and ETV are well tolerated in these patients, with an improvement in virological, biochemical and clinical parameters [85]. Recently, a meta-analysis showed that LAM and TBV significantly decrease the mortality rate and disease severity in patients with decompensated cirrhosis. Also, both of them promote HBeAg seroconversion in these patients [86]. NAs with low rates of inducing drug-resistant mutations and powerful and rapid HBV suppressive function, such as ETV or TDF, could be regarded as the first-line drugs for NAs-naive patients with decompensated cirrhosis for long-term therapy [84-86]. Even with low doses, the application of IFN-α in patients with HBV-related decompensated cirrhosis can facilitate clinical decompensation and increase the risk of bacterial infection [87]. IFN is contraindicated in patients with HBV-related decompensated cirrhosis in the era of NAs. The studies using antivirals for the treatment of cirrhosis are listed in Table 1.

Antiviral therapy using newer NAs could delay or obviate liver transplantation in some patients [86]. Some clinical guidelines suggest that the clinical improvement in some wait-listed patients with antiviral therapy could lead to their retreat from the transplant list [98,99]. However, if the decompensation is caused by superimposed viral infection, the effect of anti-HBV therapy would be limited. In this situation, liver transplantation should be the most immediate option. Standard of therapy for patients with HBV-related decompensated cirrhosis in accordance with their clinical manifestations, including control of ascites, infection or encephalopathy, should be instituted quickly and sufficiently [99]. Monitoring of HCC and timely transferring consultation for liver transplantation are also mandatory [99,100].

**Antiviral treatment of HCV-related cirrhosis**

The antiviral treatment of HCV-related cirrhosis poses much greater challenges. IFN remains an essential element of HCV antiviral treatment, but has reduced efficacy and significant toxicity at this stage of cirrhosis [90]. The current standard of care for HCV patients is the therapy with pegylated interferon (Peg-IFN) and ribavirin (RBV), leading to 45% of cure for genotype 1 HCV patients and approximately 80% for patients infected with HCV genotypes 2 and 3 [91]. The current standard of care for chronic hepatitis C is the combination of PEG-IFNa and RBV [92]. A recent study provides solid evidence that anti-HCV treatment using recombinant or pegylated IFN plus RBV is equally effective in compensated cirrhosis both before and after liver transplantation [97]. Several clinical trials have demonstrated that the new direct acting antivirals, such as Sofosbuvir, Daclasta- vir, Asunaprevir, ABT-450, Faklaprevir, Simeprevir, and Deleobuvir, interact with several of vital components of HCV (NS3/4, NS5A, NS5B polymerase, etc.) and have a chance of viral eradication of 80%-90%, with a few negligible side effects [98]. The combination of vaniprevir (a NS3/4A protease inhibitor) with Peg-IFN plus RBV significantly increase rates of sustained virologic response (SVR) among treatment-experienced patients with chronic HCV genotype 1 infection, compared to re-treatment with Peg-IFN plus RBV alone. Vaniprevir
is generally well-tolerated for up to 48 wk in those with compensated cirrhosis. Eltrombopag (an oral, non-peptide, thrombopoietin receptor agonist) can significantly increase platelet numbers in thrombocytopenic patients with HCV-induced cirrhosis, allowing otherwise ineligible or marginal patients to begin and maintain antiviral therapy and leading to significantly increased rates of SVR. It has been well-established that the CC genotype of the genetic polymorphism rs12979860 located at 3 kilobases upstream of the IL28B gene, encoding IFN-lambda-3, is associated with spontaneous clearance of HCV infection and an approximately 2-fold change in response to treatment with Peg-IFN plus RBV. The frequency of C allele of rs12979860 is 80.3% in subjects of European ancestry and 56.2% in those of African ancestry, which might be one of reasons why the European population is more apt to eradicate HCV than the African population. The frequency of rs12979860 CC genotype is 84.1% in Chinese HCV-positive patients, indicating that HCV-related cirrhosis in Chinese HCV carriers should not be as common as in HCV carriers of African ancestry. Subsequent studies have also demonstrated that the IL-28B rs8099917 genotype TT significantly predict SVR in patients chronically infected with HCV genotype 1 to PEG-IFN-RBV therapy. The prediction of nonresponse to the treatment is mandatory to avoid side effects and reduce costs. Genotyping the IL-28B rs12979860 and/or rs8099917 is mandatory to avoid side effects and reduce costs. Genotyping the IL-28B rs12979860 and/or rs8099917 should be considered before the treatment of HCV-related cirrhosis. The baseline mean model of end stage-liver disease (MELD) score predicts the risk of hepatic decompensation during antiviral therapy. Patients with the CC genotype of rs12979860 and/or the TT genotype of rs8099917 polymorphisms should be considered for the treatment of HCV-related cirrhosis.

Potential stem cell treatment for decompensated cirrhosis

Liver transplantation is the currently last option for the

Table 1 Current regimes of antiviral treatment for virus-related cirrhosis

| Medicine used | Number of patients | Virological responses | Survival | Ref. |
|---------------|--------------------|-----------------------|----------|------|
| HBV-related cirrhosis | ETV (1.0 mg/d) or ADV (10 mg/d) | Treated: IFN | 75% and 20% of subjects achieve HBV DNA undetectable after 48 wk (ETV and ADV, respectively) | Overall 1-yr patient survival rates were 84% and 83% (ETV and ADV, respectively) | [83] |
| | TBV (600 mg/d) or LAM (100 mg/d) | Group 1: PegIFN-2a + RBV | 69%, 52% and 59% achieve SVR after 24 wk (group 1, group 2 and group 3, respectively) | Not analyzed | [81] |
| | ETV (0.5 mg/d) | Group 2: PegIFN-2b + RBV | 70.5%, 87.8% and 72.7% achieve HBV DNA undetectable after 48 wk (TDF, TDF plus FTC, ETV, respectively) | Not analyzed | [84] |
| | TDF (300 mg/d) or FTC (300 mg/d) + ETV (0.5 mg/d) | Group 3: PegIFN-2a + placebo | 59% and 40% achieve HBV DNA undetectable after 48 wk (wait-listed and post transplantation, respectively) | Overall 1-yr patient survival rates were 86% and 91% (wait-listed and post transplantation, respectively) | [87] |
| HCV-related cirrhosis | ADV (10 mg/d) | Treated: IFN | 69.8% and 40% achieve SVR after 48 wk (TDF, TDF plus FTC, ETV, respectively) | | |
| | | Group 1: PegIFN-2a + RBV | 69.8% and 40% achieve SVR after 48 wk (TDF, TDF plus FTC, ETV, respectively) | | |
| | Non-LT and LT cirrhotic patients are all treated for PEG-IFN a2a or a2b plus RBV | 72 patients in both treated group and untreated group | 5-yr overall survival is 50% and 39% in treated and untreated group, respectively | | |
| | HBV-related cirrhosis | Group 1: PegIFN-2a + RBV | 453 in group 1, 444 in group 2 and 224 in group 3 | | |
| | | Group 2: PegIFN-2b + RBV | 69%, 52% and 59% achieve SVR after 24 wk (group 1, group 2 and group 3, respectively) | | |
| | | Group 3: PegIFN-2a + placebo | 72 patients in both treated group and untreated group | Not analyzed | [89] |
| | | Non-LT and LT cirrhotic patients are all treated for PEG-IFN a2a or a2b plus RBV | 43 HCV non-LT cirrhotic patients and 17 LT HCV-related cirrhotic patients | Not analyzed | [87] |

1Undetectable HCV RNA in serum after 24 wk of post-treatment follow-up; 2Once-weekly injections of 180 mcg of PegIFN-a2a plus RBV (1000 mg/d); 3Thrice-weekly injections of 3 million units of PegIFN-a2b plus RBV (1000 mg/d); 4Once-weekly injections of 180 mcg of PegIFN-a2a plus daily placebo; 5Treatment started with 1 mega unit three times weekly for three months then increased every three months to 3, 6, and 9 mega units; 6PEG-IFN-a2a or -a2b at the dose of 180 mcg/wk or 1.5 mcg/kg per week respectively; and RBV 800-1200 mg, based on body weight. HBV: Hepatitis B virus; ETV: Entecavir; TBV: Telbivudine; LAM: Lamivudine; ETV: Entecavir; ADV: Adefovir; TDF: Tenofovir disoproxil fumarate; FTC: Emtricitabine; HCV: Hepatitis C virus; SVR: Sustained virological response; PegIFN: Peginterferon; RBV: Ribavirin; CHB: Chronic hepatitis B; IFN: Interferon; LT: Liver transplanted; EVR: Early virological response.

Eltrombopag (an oral, non-peptide, thrombopoietin receptor agonist) can significantly increase platelet numbers in thrombocytopenic patients with HCV-induced cirrhosis, allowing otherwise ineligible or marginal patients to begin and maintain antiviral therapy and leading to significantly increased rates of SVR. It has been well-established that the CC genotype of the genetic polymorphism rs12979860 located at 3 kilobases upstream of the IL28B gene, encoding IFN-lambda-3, is associated with spontaneous clearance of HCV infection and an approximately 2-fold change in response to treatment with Peg-IFN plus RBV. The frequency of C allele of rs12979860 is 80.3% in subjects of European ancestry and 56.2% in those of African ancestry, which might be one of reasons why the European population is more apt to eradicate HCV than the African population. The frequency of rs12979860 CC genotype is 84.1% in Chinese HCV-positive patients, indicating that HCV-related cirrhosis in Chinese HCV carriers should not be as common as
treatment of virus-related decompensated cirrhosis patients who fail to respond to antiviral treatments. Due to the lack of donors, surgical complications, rejection reactions, and high cost for liver transplantation, other strategies have been considered for the treatment of decompensated cirrhosis. Of those, stem cell-based treatments can be expected to be an alternative for patients with liver failure or decompensated cirrhosis because it may improve scarring and supplement hepatocytes. Repopulation induced hepatic stem cells (iHepSCs) can become hepatocyte-like cells in the injured liver of fulminant acetate hydrolase (Fah)-deficient mice. Mesenchymal stem cells (MSCs) produce inhibitory cytokines or induce the development of regulatory T cells in the inflammatory and fibrotic processes, therefore they play an immunomodulatory role in this process although many details remain unknown. Interestingly, MSC therapy seems to be effective in regulating the immune response in liver injury, transplantation, and autoimmunity in both patients in clinical trials and animal models of liver disease. MSCs can directly suppress the activation of the main cell source of ECM, HSCs, via MSC-derived IL-10 and TNF-α, and may also induce HSC apoptosis via the Fas/FasL pathway. Therefore, MSCs are considered to work through multiple mechanisms to harmonize a dynamic, integrated response to liver inflammation and fibrosis, which prevents the progressive distortion of hepatic architecture.

Another actual objective of MSC treatment is to substitute impaired hepatocytes in patients with liver failure or decompensated cirrhosis with exogenous functional hepatocytes. For this reason, induced pluripotent stem (iPS) cells and embryonic stem (ES) cells have been shown to be the most competent, producing large numbers of functional hepatocyte-like cells (HLCs) in both animal models and humans. However, ethical issues and indeterminacy about their reaction in vivo in a proper homoeostatic manner have limited their clinical applications. It is currently unknown whether MSC therapy could induce side effects such as hepatic artery dissection, fibrogenesis, and even tumorigenesis. The long-term clinical significance and safety of stem cell-based therapies should be confirmed in large-scale randomized controlled trials. Thus, the co-transplantation of iPS/ES-derived MSCs and HLCs may offer the potency for a series of new therapeutic interventions for liver diseases. It will be highly important to tailor future stem cell therapies to specific patient types due to the mutable feature of different stem cells (ES, iPS, and MSCs).

Regenerative therapies have the potential to provide minimally invasive procedures with few complications. The potential for stem cells in bone marrow (BM) to differentiate into hepatocytes and intestinal cells was confirmed through detection of Y chromosome-containing cells in samples from female recipients of BM cells (BMCS) from male donors. Recent studies showed that use of whole bone marrow as a cell therapy in a rodent model with chronic liver disease led to the evolution of hepatic fibrosis. These studies suggest that BMCS are effective sources for regenerative liver therapy. A study group have found that targeting androgen receptor, which is a key factor in male sexual phenotype in bone marrow mesenchymal stem cells (BM-MSCs), can improve the therapeutic efficacy of transplantation for liver fibrosis. Autologous BMC infusion (ABMI) in patients with cirrhosis is one of regenerative therapies. Serum albumin levels and Child-Pugh scores significantly improved after ABMI therapy, and the most important is lack of adverse effects. Thus, ABMI therapy should be developed as a hopeful option for the treatment of decompensated cirrhosis.

CONCLUSION

The process of virus-induced cirrhosis is a dynamic, multifaceted network. Inflammation provides a suitable microenvironment for the evolution of viral mutation-selection-adaptation, which in turn causes disease-specific viral mutation pattern. The repeated liver damage and tissue repair eventually progress to fibrosis and cirrhosis. In this process, both HSCs and macrophages are important for the fibrogenesis via excessive accumulation of ECM, and macrophages also promote the formation of fibrosis. Oral NAs can prevent viral replication efficiently in viral-related decompensated cirrhosis, cause the stabilization or improvement of liver function, and improve survival. Antiviral treatment should be started as early as the diagnosis has been confirmed. Targeting key signaling pathway should be effective in halting the progression of cirrhosis. Moreover, stem cell-based treatments could be an option for patients with liver failure or decompensated cirrhosis. Future studies should focus more on insight into the cross-link between the mechanisms and therapeutic options.

REFERENCES

1. Perez JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538 [PMID: 16879891 DOI: 10.1016/j.jhep.2006.05.013]
2. Zhang HW, Yin JH, Li YT, Li CZ, Ren H, Gu CY, Wu HY, Liang XS, Zhang P, Zhao JF, Tan XJ, Lu W, Schaefer S, Cao GW. Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China. Gut 2008; 57: 1713-1720 [PMID: 18755887 DOI: 10.1136/gut.2008.157149]
3. Yin J, Zhang H, He Y, Xie J, Liu S, Chang W, Tan X, Gu C, Lu W, Wang H, Bi S, Cui F, Liang X, Schaefer S, Cao G. Distribution and hepatocellular carcinoma-related viral properties of hepatitis B virus genotypes in Mainland China: a community-based study. Cancer Epidemiol Biomarkers Prev 2010; 19: 777-786 [PMID: 20160279 DOI: 10.1158/1055-9965.EPI-09-1001]
4. Yin J, Zhang H, Li C, Gao C, He Y, Zhai Y, Zhang P, Xu L, Tan X, Chen J, Cheng S, Schaefer S, Cao G. Role of hepatitis B virus genotype mixture, subgenotypes C2 and B2 on hepatocellular carcinoma: compared with chronic hepatitis B and asymptomatic carrier state in the same area. Carcinogenesis 2008; 29: 1685-1691 [PMID: 18192693 DOI: 10.1093/car-
Lin J et al. Mechanism and treatment of liver cirrhosis
Lin J et al. Mechanism and treatment of liver cirrhosis

58: 254-257 [PMID: 23831131 DOI: 10.1016/j.jcv.2013.06.014]

33 Ezikiori S, Alaoui R, Rebbani K, Ibrahim I, Fakhir FZ, Nadir S, Diepolder H, Khakoo SI, Thursz M, Benjelloun S. Genetic variation in the interleukin-2R α gene is associated with spontaneous clearance and progression of hepatitis C virus in Moroccan patients. PLoS One 2013; 8: e54793 [PMID: 23358556 DOI: 10.1371/journal.pone.0054793]

34 Sarobe P, Lasarte JI, Cañes N, López-Díaz de Cerio A, Baixeras E, Labarga P, García N, Borràs-Cuesta F, Prieto J. Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol 2002; 76: 5062-5070 [PMID: 11967322 DOI: 10.1128/JVI.76.10.5062-5070.2002]

35 Radzievich H, Ibegbo CC, Fernandez ML, Workowski KA, Obideen K, Wehbi M, Hanson H, Steinberg JP, Masopust D, Wherry EJ, Altman JD, Rouse BT, Freeman GJ. Grakoui A. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 2007; 81: 2545-2553 [PMID: 17182670 DOI: 10.1128/JVI.02021-06]

36 Golden-Mason L, Palmer B, Klarquist J, Mengshoel JA, Carpenter JP, Schurman S, Patel V, Brotman B, Izadnia M, Halliday J, Waldman A, Zhang Q, Chang W, Du Y, Zhang H, Cao G. Viral amino acid substitution rate and low levels of heterogeneity in hepatitis B virus over 25 years. J Virol 2004; 78: 9808-9822 [PMID: 18667031 DOI: 10.1128/JVI.10075-08]

37 Yao QZ, Simaan R, Rupani B, Koon J, Ge Y, Zhang S, Zhao J, Zhang Q, Ni W, Wang H, Cao G. Association between the various mutations in viral core promoter region and host inflammation-related factors that can predict the occurrence and prognosis of hepatitis C virus infection in Moroccan patients. WJG 2013; 19: 4258-4270 [PMID: 22090781 DOI: 10.3748/wjg.v17.i38.4258]

38 Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol 2007; 7: 875-888 [PMID: 17948021 DOI: 10.1038/nri2189]

39 Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G. Viral and host inflammation-related factors that can predict the progression of hepatocellular carcinoma. Eur J Cancer 2012; 48: 1977-1987 [PMID: 22325840 DOI: 10.1016/j.ejca.2012.01.015]

40 Han YF, Zhao J, Ma LY, Yin JH, Chang WJ, Zhang HW, Cao GW. Factors predicting occurrence and prognosis of hepatitis-B virus-related hepatocellular carcinoma. World J Gastroenterol 2011; 17: 4258-4270 [PMID: 22090781 DOI: 10.3748/wjg.v17.i38.4258]

41 Bieche I, Asselah T, Laurendeau I, Vidaud D, Degot C, Paradis V, Bedossa P, Valla DC, Marcellin P, Vidaud M. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology 2005; 332: 130-144 [PMID: 15661146 DOI: 10.1016/j.virol.2004.11.009]

42 Takahara Y, Takahashi M, Zhang QW, Watanabe M, Mori M, Tamari A, Shioji M, Nishiguchi S. Serial changes in expression of functionally clustered genes in progression of liver fibrosis in hepatitis C patients. World J Gastroenterol 2008; 14: 2010-2022 [PMID: 18395900 DOI: 10.3748/wjg.v14.i14.2010]

43 Utsunomiya T, Okamoto M, Hashimoto M, Yoshinaga K, Shiraiishi T, Tanaka F, Mimori K, Inoue H, Watanabe G, Barnard GF, Mori M. A gene-expression signature can quantify the degree of hepatic fibrosis in the rat. J Hepatol 2004; 41: 399-406 [PMID: 15336442 DOI: 10.1016/j.jhep.2004.05.015]

44 Tacke F, Luedde T, Trautwein C. Inflammatory pathways in liver homeostasis and liver injury. Clin Rev Allergy Immunol 2009; 36: 4-12 [PMID: 18600481 DOI: 10.1007/s12016-008-8091-0]

45 Hösel M, Quasdorf M, Wiegmann K, Webb D, Zedler U, Broxtermann M, Tedjokusumo R, Esser K, Arzberger S, Kirschning CJ, Langenkamp A, Falk C, Bühning H, Rose-John S, Prozter U. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 2009; 50: 1773-1782 [PMID: 19937696 DOI: 10.1002/hep.23226]

46 Berkham-Kamphorst E, Stoll D, Gressner AM, Weiskirchen R. Antisense strategy against PDGF-B chain proves effective in preventing experimental liver fibrogenesis. Biochem Biophys Res Commun 2004; 321: 413-423 [PMID: 15358192 DOI: 10.1016/j.bbrc.2004.06.153]

47 Wietzke-Braun P, Manhardt LB, Rosenberger A, Uy A, Ramadori G, Mihael D. Spontaneous elimination of hepatitis C virus infection: a retrospective study on demographic, clinical, and serological correlates. World J Gastroenterol 2007; 13: 4224-4229 [PMID: 17696252]

48 Bowen DG, Walker CM. Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med 2005; 201: 1709-1714 [PMID: 15939787 DOI: 10.1084/jem.20050808]

49 Fernandez J, Taylor D, Morhardt DR, Mihalik K, Puig M, Rice CM, Feinstone SM, Major ME. Long-term persistence of hepatitis C virus in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity. J Virol 2004; 78: 9782-9789 [PMID: 15331711 DOI: 10.1128/JVI.78.18.9782-9789.2004]

50 Osiowy C, Giles E, Tanaka Y, Mizokami M, Minuk GY. Molecular evolution of hepatitis B virus over 25 years. J Virol 2006; 80: 10307-10314 [PMID: 17041211 DOI: 10.1128/JVI.00996-06]

51 Peng ZG, Zhao ZY, Li YP, Wang YP, Hao LH, Fan B, Li YH, Wang YM, Shan YQ, Han YX, Zhu YP, Li JR, You XF, Li ZR, Jiang JD. Host apolipoprotein B messenger RNA-editing enzyme catalytic polypeptide-like 3G is an innate defensive factor and drug target against hepatitis C virus. Hepatology 2011; 53: 1080-1089 [PMID: 21480314 DOI: 10.1002/hep.24160]

52 Vartanian JP, Henry M, Marchio A, Suspène R, Aynaud MM, Guertard D, Cervantes-Gonzalez M, Battiston C, Mazzaferro V, Pineau P, Dejean A, Wain-Hobson S. Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog 2010; 6: e1000928 [PMID: 20523896 DOI: 10.1371/journal.ppat.1000928]

53 Yin J, Xie J, Liu S, Zhang H, Han L, Lu W, Shen Q, Xu G, Dong H, Shen J, Zhang J, Han J, Wang L, Liu Y, Wang F, Zhao J, Zhang Q, Ni W, Wang H, Cao G. Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic
carrier state to hepatocellular carcinoma. Am J Gastroenterol 2011; 106: 81-92 [PMID: 20959817 DOI: 10.1038/ajg.2010.399]

58 Zhang Q, Yin J, Zhang Y, Deng Y, Ji X, Du Y, Pu R, Han Y, Zhao J, Han X, Zhang H, Cao G. HLA-DP polymorphisms affect the outcomes of chronic hepatitis B virus infections, possibly through interacting with viral mutations. J Virol 2013; 87: 12176-12186 [PMID: 24006435 DOI: 10.1128/JVI.02073-13]

59 Chen CH, Hung CH, Lee CM, Hu TH, Wang JH, Wang JC, Lu SN, Changchien CS. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBsAg-negative patients. Gastroenterology 2007; 133: 1466-1474 [PMID: 17915220 DOI: 10.1053/j.gastro.2007.09.002]

60 Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, Cao G. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Canc Inst 2009; 101: 1066-1082 [PMID: 19574418 DOI: 10.1093/jnci/djp180]

61 Tamori A, Kawada N. HLA class II associated with outcomes of hepatitis B and C infections. World J Gastroenterol 2013; 19: 5395-5401 [PMID: 24023482 DOI: 10.3748/wjg.v19.i33.5395]

62 Kitab B, Essaid El Feydi A, Afifi R, Trepo C, Benazzouz M, Essami W, Zouloum F, Chemin I, Al HS, Ezzikouri S, Benjelloun S. Variability in the precore and core promoter regions of HBV strains in Morocco: characterization and impact on liver disease progression. PLoS One 2012; 7: e42891 [PMID: 22905181 DOI: 10.1371/journal.pone.0042891]

63 Lee JH, Han KH, Lee JM, Park JH, Kim HS. Impact of hepatitis B virus (HBV) x gene mutations on hepatocellular carcinoma development in chronic HBV infection. Clin Immunol 2011; 18: 914-921 [PMID: 21490166 DOI: 10.1128/CVI.00474-10]

64 Brenner DA, Kisseleva T, Scholten D, Paik YH, Iwaisako K, Inokuchi S, Schnabl B, Tauras K. Origin of myofibroblasts in liver fibrosis. Fibrogenesis Tissue Repair 2012; 5 Suppl 1: S17 [PMID: 23295769 DOI: 10.1186/1755-1536-5-S1-S17]

65 Friedman SL. Hepatic stellate cells: prostates, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88: 125-172 [PMID: 18195085 DOI: 10.1152/physrev.0013.2007]

66 Jiang JX, MiKami K, Shah VH, Torok NJ. Hepatitis C virus induces interleukin-1β (IL-1β)/IL-18 in circulatory and resident liver macrophages. J Virol 2013; 87: 12284-12290 [PMID: 24006444 DOI: 10.1128/JVI.01962-13]

Lin J et al. Mechanism and treatment of liver cirrhosis

72 Sica A, Invernizzi P, Mantovani A. Macrophage plasticity and polarization in liver homeostasis and pathology. Hepatology 2014; 59: 2034-2044 [PMID: 24151204 DOI: 10.1002/hep.26754]

73 Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis 1999; 19: 129-140 [PMID: 10422196 DOI: 10.1055/s-2007-1007105]

74 Dufeld JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, Wu S, Lang R, Iredale JP. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005; 115: 56-65 [PMID: 15630444 DOI: 10.1172/JCI200522675]

75 Chen LP, Zhao J, Du Y, Han YF, Su T, Zhang HW, Cao GW. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol 2012; 1: 174-183 [PMID: 21475223 DOI: 10.5501/wjv.v1.i6.174]

76 Papatheodoridis GV, Manolakopoulos S, Archimandritis AJ. Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol 2008; 14: 6902-6910 [PMID: 19058523 DOI: 10.3748/wjg.v14.6.6902]

77 Yuen MF, Lai CL. Treatment of chronic hepatitis B: Evolution over two decades. J Gastroenterol Hepatol 2011; 26 Suppl 1: 138-143 [PMID: 21199525 DOI: 10.1111/j.1440-1746.2010.06545.x]

78 Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662 [PMID: 19714720 DOI: 10.1002/hep.23190]

79 Mutimer DJ, Lok A. Management of HBV- and HCV-induced end stage liver disease. Gut 2011; 61 Suppl 1: i59-i67 [PMID: 22504920 DOI: 10.1136/gutjnl-2012-302076]

80 Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012; 57: 442-450 [PMID: 22904333 DOI: 10.1016/j.jhep.2012.02.033]

81 Roche B, Samuel D. Treatment of patients with HBV-related decompensated cirrhosis and liver transplanted patients. Clin Liver Dis 2013; 17: 451-473 [PMID: 23905816 DOI: 10.1016/j.cld.2013.05.003]

82 Chen YC, Chu CM, Yeh CT, Liaw YF. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int 2007; 1: 267-273 [PMID: 17966589 DOI: 10.1007/s12177-007-0301-0]

83 Dakin H, Figler C, Harper C. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Value Health 2010; 13: 934-945 [PMID: 20825624 DOI: 10.1111/j.1524-4733.2010.00777.x]

84 Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandeewa T, Leung N, Peng CY, Myers RP, Brown RS, Jeffers L, Tsai N, Bialkowski J, Tang S, Beebe S, Coomey E. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011; 54: 91-100 [PMID: 21503940 DOI: 10.1002/hep.23461]

85 Liaw YF, Sheen IS, Lee CM, Akara US, Papatheodoridis GV, Suet-Hing Wong F, Chang TT, Horban A, Wang C, Kwan P, Buti M, Prieto M, Berg T, Kitrinos K, Peschell K, Houng SG, Choudhuri G, Safadi R, Twardosz T, Prabhakar B, Hwang SG, Chou S, Safadi R, Tanwandeewa T, Chutaputti C, Bao W, Avila
Mechanism and treatment of liver cirrhosis

C. Trylesinski A. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related compensated cirrhosis. J Viral Hepat 2012; 19: 732-743 [PMID: 22967105 DOI: 10.1111/j.1365-3156.2012.01601.x]

Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh D. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related compensated cirrhosis. J Hepatol 2010; 52: 176-182 [PMID: 20006394 DOI: 10.1016/j.jhep.2009.11.007]

Schiff E, Lai CL, Hadzijamanić S, Neuhaus P, Terrault N, Colombo M, Tillmann H, Samuel D, Zeuzem S, Villeneuve JP, Arturburn S, Borroto-Esoda K, Brosgart C, Chuck S. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13: 349-360 [PMID: 17326221 DOI: 10.1002/lt.20981]

Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, Anschuetz G, Davis R, Gardner SD, Brown NA. Determinants of early mortality in patients with compensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123: 719-727 [PMID: 12198698]

Lian JS, Zeng LY, Chen JY, Jia HY, Zhang YM, Xiang DR, Yu L, Hu JH, Li YE, Zheng L, Li LJ, Yang YD. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related compensated cirrhosis. World J Gastroenterol 2013; 19: 6278-6283 [PMID: 24115827 DOI: 10.3748/wjg.v19.i37.6278]

European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]

Garcia-Tsao G, Lim JK. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009; 104: 1802-1829 [PMID: 19455106 DOI: 10.1038/ajg.2009.191]

Murray KF, Carithers RL. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology 2005; 41: 1407-1432 [PMID: 15880505 DOI: 10.1002/heap.20074]

Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux F. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2004; 350: 292-296 [PMID: 15077980 DOI: 10.1016/j.jhep.2013.01.018]

Forsyth SJ, Newsome PN. New horizons for stem cell therapy in liver disease. J Hepatol 2012; 56: 496-499 [PMID: 21978218 DOI: 10.1016/j.jhep.2011.06.022]

Yu B, He ZY, You P, Han QW, Xiang D, Chen F, Wang MJ, Liu CC, Lin XW, Borjigin U, Zi XY, Li JX, Hu YL, Li WL, Han CS, Wangensteen KJ, Shi Y, Hui LJ, Wang X, Hu YP. Reprogramming fibroblasts into bipotential hepatic stem cells by defined factors. Cell Stem Cell 2013; 13: 328-340 [PMID: 23876105 DOI: 10.1016/j.stem.2013.06.017]

Sun L, Akiyama K, Zhang H, Yamazaki T, Hou Y, Zhao S, Xu T, Le A, Shi S. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009; 27: 1421-1432 [PMID: 19489103 DOI: 10.1002/stem.68]

Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8: 726-736 [PMID: 19172693 DOI: 10.1038/nri2959]

Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamazaki T, Cai T, Chen W, Sun L, Shi S. Mesenchymal-stem-cell-induced immunomodulation involves FAS-ligand/FAS-mediated T cell apoptosis. Cell Stem Cell 2012; 10: 544-555 [PMID: 22542159 DOI: 10.1016/j.stem.2012.03.007]

Huang P, He Z, Ji S, Sun H, Xiang D, Liu C, Hu Y, Wang X, Hui L. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature 2011; 475: 386-389 [PMID: 21562492 DOI: 10.1038/nature10116]

Theise ND, Nimmakayalu M, Gardner R, Illeib PB, Morgan G, Teperman L, Henegariu O, Krause DS. Liver from
bone marrow in humans. *Hepatology* 2000; 32: 11-16 [PMID: 10869283]

114 **Alison MR**, Poulson R, Jeffery R, Dhillon AP, Quaglia A, Jacob J, Novelli M, Prentice G, Williamson J, Wright NA. Hepatocytes from non-hepatic adult stem cells. *Nature* 2000; 406: 257 [PMID: 10917519 DOI: 10.1038/35018642]

115 **Okamoto R**, Yajima T, Yamazaki M, Kanai T, Mukai M, Okamoto S, Ikeda Y, Hibi T, Inazawa J, Watanabe M. Damaged epithelia regenerated by bone marrow-derived cells in the human gastrointestinal tract. *Nat Med* 2002; 8: 1011-1017 [PMID: 12195435 DOI: 10.1038/nm755]

116 **Thomas JA**, Pope C, Wojtacha D, Robson AJ, Gordon-Walker TT, Hartland S, Ramachandran P, Van Deemter M, Humen DA, Iredale JP, Forbes SJ. Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function. *Hepatology* 2011; 53: 2003-2015 [PMID: 21433043 DOI: 10.1002/hep.24315]

117 **Huang CK**, Lee SO, Lai KP, Ma WL, Lin TH, Tsai MY, Luo J, Chang C. Targeting androgen receptor in bone marrow mesenchymal stem cells leads to better transplantation therapy efficacy in liver cirrhosis. *Hepatology* 2013; 57: 1550-1563 [PMID: 23150236 DOI: 10.1002/hep.26135]

118 **Terai S**, Ishikawa T, Omori K, Aoyama K, Marumoto Y, Urata Y, Yokoyama Y, Uchida K, Yamasaki T, Fujiy O, Okita K, Sakaoka Y. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. *Stem Cells* 2006; 24: 2292-2298 [PMID: 16778155 DOI: 10.1634/stemcells.2005-0542]

**P- Reviewers**: Amarapurkar DN, Chuang WL, Ido A, Lin ZY, Schemmer P, Tasci I **S- Editor**: Ma YJ **L- Editor**: Wang TQ **E- Editor**: Zhang DN
